This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Chronic acquired pure red cell aplasia만성 후천성 순수적혈구무형성

ICD-10: D60.0 | Synonyms: Chronic acquired PRCA, Pure red cell aplasia, Erythroblastopenia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early description and naming

The concept of pure red cell aplasia (PRCA) began in 1922 when Kaznelson first described a case of severe anemia in an adult with bone marrow findings showing selective deficiency of only erythroid cells. In 1936, Josephs separately described chronic PRCA occurring in children, and later Diamond and Blackfan systematically classified the congenital form, establishing the distinction between acquired and congenital PRCA.

Association between thymoma and PRCA

Over the 1960s, it was found that thymoma accompanies about 50% of adult patients with chronic PRCA. In 1967, Hirst and Robertson systematically analyzed cases in which PRCA improved after thymoma removal and were the first to argue that thymic immune abnormalities are associated with the development of PRCA. This became the starting point for research on autoimmune mechanisms.

Elucidation of autoimmune mechanisms

In the 1970s–1980s, as the effectiveness of immunosuppressive therapy (steroids, cyclosporine) was reported, autoimmune mechanisms came to be recognized as the main pathogenesis. In particular, in 2002 Johnson et al. reported PRCA caused by anti-EPO antibodies after administration of recombinant erythropoietin (rHuEPO), raising awareness of iatrogenic PRCA.

2. Causes

Autoimmune mechanisms and primary PRCA

In primary (idiopathic) PRCA, where the cause is not clear, autoimmune mechanisms are regarded as the most important cause. T lymphocytes (especially CD8+ cytotoxic T cells) directly destroy erythroblasts, the red cell precursors, or autoantibodies (IgG) are produced against red cell precursors or erythropoietin (EPO), suppressing red cell production.

Thymoma-associated PRCA

Thymoma is the neoplasm most commonly associated with chronic acquired PRCA, observed in about 15–50% of all adult PRCA. Immune dysregulation by thymoma is understood to induce the production of autoreactive T cells and autoantibodies. PRCA sometimes improves after thymoma resection, but additional immunosuppressive therapy is often needed.

Iatrogenic and infectious causes

PRCA due to anti-EPO antibody formation after administration of recombinant erythropoietin (rHuEPO) has been reported. Parvovirus B19 infection mainly causes transient PRCA, but in immunocompromised patients it can lead to persistent PRCA due to chronic infection. Other drugs (penicillin, rifampin, azathioprine, etc.), autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis), pregnancy and hematologic malignancies (chronic lymphocytic leukemia, large granular lymphocytic leukemia) are also causes.

3. Genetics

Genetic characteristics as an acquired disease

Chronic acquired PRCA is basically not a hereditary disease, and no specific gene mutation is a direct cause. However, there are reports that certain HLA types (HLA-DR2, HLA-DR4, HLA-DQ7) related to autoimmune predisposition are associated with primary PRCA.

HLA associations and immune predisposition

Some studies have reported an increased risk of rHuEPO-related PRCA in individuals with the HLA-DRB1*04 allele. In thymoma-associated PRCA, clonal rearrangement of specific T-cell receptor genes is observed, reflecting the selective expansion of clonal T-cell populations targeting red cell precursors.

Association with large granular lymphocytic leukemia

Large granular lymphocytic (LGL) leukemia or clonal LGL proliferation accompanies some (about 10–15%) patients with chronic PRCA. In such cases, STAT3 gene mutations (especially STAT3 Y640F) are frequently found, providing a molecular link between PRCA and LGL leukemia.

4. General epidemiology

Worldwide prevalence and incidence

Chronic acquired PRCA is a rare disease, and accurate prevalence data are limited. The estimated annual incidence is about 1–2 per million, occurring mainly in adults. The median age of onset is in the 50s–60s, with almost no difference between men and women.

Status in Korea

In Korea, chronic acquired PRCA is listed on the national rare disease list. Accurate national epidemiological data are lacking, but it is estimated that dozens of new diagnoses are made each year at specialized hematology centers. Thymoma-associated PRCA and idiopathic PRCA make up the main types among Korean patients. Under the national rare disease support policy, Special Copayment Reduction can be applied.

Age and sex distribution

Chronic acquired PRCA occurs mainly in middle-aged to elderly adults and is rare in children under 20. Thymoma-associated PRCA is most common in adults in their 40s–60s. rHuEPO-associated PRCA occurs in patients with chronic renal failure (mainly dialysis patients).

5. Pathophysiology

T cell-mediated immune suppression

The main pathogenesis of chronic acquired PRCA is direct destruction of red cell precursors (erythroid colony-forming units, BFU-E and CFU-E) by CD8+ cytotoxic T cells. These autoreactive T cells respond to surface antigens of red cell precursors and induce cell death through the perforin-granzyme pathway or the Fas-FasL pathway. Release into peripheral blood of autoreactive T-cell clones derived from thymoma, due to abnormalities in the thymic selection process, is understood to be the core pathogenesis of thymoma-associated PRCA.

Autoantibody-mediated mechanism

IgG autoantibodies can target the EPO receptor or EPO itself and block red cell production. In rHuEPO-related PRCA, anti-EPO neutralizing antibodies form due to increased immunogenicity of the subcutaneous formulation (formulation changes, changes in preservatives, etc.). These antibodies cross-react with endogenous EPO and completely block red cell production.

Direct infection of erythroblasts by Parvovirus B19

Parvovirus B19 selectively infects red cell precursors using the P antigen (globoside) on their surface as a receptor and induces cytolysis. In immunocompetent individuals it causes transient red cell aplasia, but in patients with T-cell deficiency (HIV, transplant patients, congenital immunodeficiency) the virus replicates persistently, leading to chronic PRCA.

6. Symptoms

Anemia-related symptoms

The main symptoms of chronic acquired PRCA are symptoms due to severe anemia. Fatigue, weakness, exertional dyspnea, palpitations, headache and reduced concentration are common symptoms. When anemia progresses gradually, the body partially adapts, so only mild symptoms may appear even at relatively low hemoglobin levels.

Additional symptoms depending on the underlying disease

In patients with thymoma, symptoms due to the thymoma itself (anterior mediastinal mass, superior vena cava syndrome, cough) may be present. In patients with autoimmune disease, symptoms of the underlying autoimmune disease such as arthralgia, skin rash and dry mouth precede or accompany it. In patients with chronic renal failure, if anemia worsens suddenly during rHuEPO treatment, PRCA due to anti-EPO antibodies should be suspected.

Pattern of symptom onset

Symptoms typically progress gradually over weeks to months and often lead to transfusion-dependent anemia. Because white blood cells and platelets are normal, it is characteristic that there are no symptoms due to bleeding or infection.

7. Signs

Physical examination findings

Generalized pallor; scleral icterus is absent or mild (unlike hemolytic anemia), and the absence of splenomegaly is characteristic. In patients with thymoma, chest examination may show no specific findings, but signs of superior vena cava syndrome (facial edema, jugular venous distension) are rarely observed.

Laboratory findings

On complete blood count (CBC), normocytic normochromic anemia is characteristic, and white blood cell and platelet counts are normal. The reticulocyte count is markedly reduced (less than 0.1% or absolute count <10,000/μL) or almost absent. Serum EPO levels are markedly elevated relative to the degree of anemia. The direct antiglobulin test (Coombs test) is negative.

Bone marrow findings

Bone marrow examination is the key to the diagnosis of PRCA; bone marrow aspiration and biopsy show a marked reduction of red cell precursors (erythroblasts) (<1% or absent), while myeloid and megakaryocytic cells are maintained normally. In thymoma-associated PRCA, a small infiltration of CD8+ T cells may be observed in the bone marrow.

8. Screening

Screening with basic blood tests

PRCA is not a target of general population screening, so there is no formal screening program. However, in patients with unexplained normochromic anemia, performing a complete blood count including the reticulocyte count to confirm reticulocytopenia is the first step in screening for PRCA.

Screening of high-risk groups

In patients receiving rHuEPO for chronic renal failure, if anemia suddenly worsens or transfusion dependence develops, anti-EPO antibody screening must be performed immediately. In patients diagnosed with thymoma, regular complete blood counts are recommended to monitor for the development of PRCA.

Screening in patients with autoimmune disease

When unexplained anemia develops in patients with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome, PRCA is included in the differential diagnosis and reticulocyte count and bone marrow examination are considered.

9. Diagnosis

Diagnostic criteria

The diagnosis of chronic acquired PRCA is based on the following criteria: ① normochromic anemia (hemoglobin <10 g/dL), ② markedly reduced reticulocytes (<1% or absolute count <10,000/μL), ③ markedly reduced or absent red cell precursors on bone marrow examination, ④ normal maintenance of myeloid and megakaryocytic cells. "Chronic" is defined as symptoms persisting for 2 months or more.

Additional tests to identify the cause

To identify the cause, chest CT (to exclude thymoma), autoantibody tests (ANA, anti-dsDNA, RF), Parvovirus B19 PCR (immunocompromised patients), anti-EPO antibody testing (patients receiving rHuEPO), flow cytometry (T-cell/NK-cell immunophenotype, presence of LGL proliferation), and serum protein electrophoresis and immunofixation electrophoresis (lymphoma-associated PRCA) are performed.

Differential diagnosis

Differentiation is needed from iron deficiency anemia, anemia of chronic disease, aplastic anemia, myelodysplastic syndrome, vitamin B12/folate deficiency, hemolytic anemia and others. In differentiating from transient erythroblastopenia (D60.1), the duration criterion for "chronic" (2 months or more) is important.

10. Treatment

Treatment of the cause

When a cause is identified, its removal takes priority. When thymoma is present, thymectomy is performed; in drug-induced PRCA, discontinuation of the causative drug, and in rHuEPO-associated PRCA, immediate discontinuation of rHuEPO, are essential. In PRCA due to Parvovirus B19, intravenous immunoglobulin (IVIG) is administered.

Immunosuppressive therapy

Immunosuppressive therapy is the core treatment for chronic acquired PRCA. Prednisolone (1mg/kg/day) is used as first-line therapy, and if the response is insufficient, cyclosporine (3–5mg/kg/day) is added or used alone. Cyclophosphamide and azathioprine may also be used. As second-line therapy, antithymocyte globulin (ATG), cyclophosphamide, rituximab (an anti-CD20 monoclonal antibody), daratumumab and others are considered.

Transfusion support

Anemia is corrected with packed red cell transfusions until the effects of immunosuppressive therapy appear. When iron overload develops from chronic transfusion, iron chelation therapy is needed. Hematopoietic stem cell transplantation (HSCT) is rarely considered in refractory PRCA.

11. Prognosis

Treatment response and remission rates

In primary chronic acquired PRCA, the overall response rate to immunosuppressive therapy is about 65–80%. Cyclosporine shows a higher response rate (about 75%) than steroid monotherapy. The rate of complete remission of PRCA after thymoma resection is about 25–30%, and the rest require additional immunosuppressive therapy.

Relapse and long-term prognosis

Relapse occurs in about 30–40% of patients who achieve remission after treatment. On relapse, most respond again when retreated with the same immunosuppressive drug. Refractory PRCA that does not respond to immunosuppressive therapy has a poor prognosis due to long-term transfusion dependence and iron overload complications.

Mortality and complications

The main causes of death are iron overload from chronic transfusion (cardiac siderosis, hepatic fibrosis), infectious complications of immunosuppressive therapy and the course of underlying neoplastic disease. rHuEPO-associated PRCA mostly remits with discontinuation of rHuEPO and immunosuppressive therapy.

12. Prevention

Prevention of iatrogenic PRCA

In patients receiving rHuEPO, regular monitoring of the reticulocyte count is recommended for surveillance of anti-EPO antibodies. Using the intravenous route rather than subcutaneous injection can lower the risk of immunogenicity. When prescribing drugs that can cause drug-induced PRCA (penicillins, some anticonvulsants, antituberculosis drugs), monitoring for the development of anemia is needed.

Management of underlying disease

Early diagnosis and active treatment of underlying diseases that can cause PRCA, such as thymoma, lymphoma and autoimmune diseases, help prevent PRCA. In immunocompromised patients, prevention of Parvovirus B19 exposure and early IVIG treatment prevent progression to chronic PRCA.

Relapse prevention and follow-up

After remission, relapse is detected early by regular complete blood counts and reticulocyte count monitoring. Prevention of infection during immunosuppressive therapy (prophylactic antibiotics, prophylactic antifungals, vaccination) is important for preventing complications.

13. References

  1. Means RT Jr. Pure red cell aplasia. Blood. 2016;128(21):2504-2509.
  2. Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111(4):1010-1022.
  3. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505-514.
  4. Johnson DW, Hawley CM, Rosser B, et al. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with subcutaneous erythropoietin. N Engl J Med. 2002;346(6):469-475.
  5. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475.
  6. Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan. Haematologica. 2008;93(1):27-33.
  7. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87(7):3000-3006.
  8. Fujishima N, Hirokawa M, Fujishima M, et al. Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica. 2006;91(12):1688-1690.
  9. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336(19):1365-1372.
  10. Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001;98(2):483-485.
  11. Kim DW, Lee JS. Pure red cell aplasia: recent advances in diagnosis and treatment. Korean Journal of Hematology. 2015;50(3):134-141.
  12. Dessypris EN. Pure red cell aplasia. In: Hoffman R, et al. eds. Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018.